Study drug combination for ovarian cancer after platinum stops working
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1/2 trial tests a combination treatment for recurrent ovarian, fallopian tube, or primary peritoneal cancer when platinum chemotherapy stops working. If you qualify, the study aims to control the cancer and see how well the treatment is tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent ovarian, fallopian tube, or primary peritoneal cancer, proven by pathology (tissue testing).
- Your cancer has stopped responding to platinum chemotherapy (platinum resistance) or did not respond at all (refractory).
- You are not able to use this exact study’s liposomal doxorubicin before—previous treatment with liposomal doxorubicin usually excludes you.
- Your scans or blood test show active/recurrent disease, and you have at least one measurable spot (size rules apply).
- Your body tests look safe enough for treatment: adequate blood counts, liver function, and kidney filtering ability.
- Your heart function is strong enough (left-ventricle ejection fraction at least 55% on an echo/MUGA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
This study tests a combination of two drugs — a chemotherapy called liposomal irinotecan and an immunotherapy drug called enlonstobart — for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.